REMEGEN Reports Annual Profit of 709 Million Yuan, Turning Around from Previous Loss

Stock News02-27

REMEGEN (09995) has announced its preliminary financial results for the 2025 fiscal year. The company achieved total operating revenue of RMB 3.251 billion, representing a year-on-year increase of 89.36%. Profit attributable to owners of the parent company was RMB 709 million, marking a turnaround from a loss in the same period last year. Basic earnings per share were RMB 1.29. The company stated that the increase in operating revenue was primarily due to higher sales volumes of Telitacicept for Injection and Disitamab Vedotin for Injection, leading to increased sales revenue. Additionally, the company granted Vor Biopharma Inc. exclusive global development and commercialization rights for Telitacicept outside the Greater China region, resulting in a significant increase in technology licensing revenue.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153539601?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153539601","market":"fut","top_or_hot":-1,"title":"REMEGEN Reports Annual Profit of 709 Million Yuan, Turning Around from Previous Loss","media":"Stock News","content":"<p>REMEGEN (09995) has announced its preliminary financial results for the 2025 fiscal year. The company achieved total operating revenue of RMB 3.251 billion, representing a year-on-year increase of 89.36%. Profit attributable to owners of the parent company was RMB 709 million, marking a turnaround from a loss in the same period last year. Basic earnings per share were RMB 1.29. The company stated that the increase in operating revenue was primarily due to higher sales volumes of Telitacicept for Injection and Disitamab Vedotin for Injection, leading to increased sales revenue. Additionally, the company granted Vor Biopharma Inc. exclusive global development and commercialization rights for Telitacicept outside the Greater China region, resulting in a significant increase in technology licensing revenue.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>REMEGEN Reports Annual Profit of 709 Million Yuan, Turning Around from Previous Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nREMEGEN Reports Annual Profit of 709 Million Yuan, Turning Around from Previous Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-27 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN (09995) has announced its preliminary financial results for the 2025 fiscal year. The company achieved total operating revenue of RMB 3.251 billion, representing a year-on-year increase of 89.36%. Profit attributable to owners of the parent company was RMB 709 million, marking a turnaround from a loss in the same period last year. Basic earnings per share were RMB 1.29. The company stated that the increase in operating revenue was primarily due to higher sales volumes of Telitacicept for Injection and Disitamab Vedotin for Injection, leading to increased sales revenue. Additionally, the company granted Vor Biopharma Inc. exclusive global development and commercialization rights for Telitacicept outside the Greater China region, resulting in a significant increase in technology licensing revenue.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1064131003.USD","symbol_name":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","start_time":0,"source_url":"","article_id":"1153539601","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153539601","pubTimestamp":1772191820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"REMEGEN (09995) has announced its preliminary financial results for the 2025 fiscal year. The company achieved total operating revenue of RMB 3.251 billion, representing a year-on-year increase of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688331":"荣昌生物","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK1583":"高瓴概念","BK0239":"医药制造","09995":"荣昌生物","BK1161":"生物科技","BK1574":"生物医药B类股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"瑞美根年报盈利7.09亿元扭亏","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1,"09995":1},"content_text":"REMEGEN (09995) has announced its preliminary financial results for the 2025 fiscal year. The company achieved total operating revenue of RMB 3.251 billion, representing a year-on-year increase of 89.36%. Profit attributable to owners of the parent company was RMB 709 million, marking a turnaround from a loss in the same period last year. Basic earnings per share were RMB 1.29. The company stated that the increase in operating revenue was primarily due to higher sales volumes of Telitacicept for Injection and Disitamab Vedotin for Injection, leading to increased sales revenue. Additionally, the company granted Vor Biopharma Inc. exclusive global development and commercialization rights for Telitacicept outside the Greater China region, resulting in a significant increase in technology licensing revenue.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153539601","isCrawlerRequest":true}